 |
 Video: What is a Stock Split?
|
|
|
| Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the oncology medicines that inhibit deoxyribonucleic acid damage repair and cause cancer cell death in specific subsets of cancer patients through a therapeutic strategy known as synthetic lethality. Co.'s primary program, CYT-0851, was identified through a phenotypic screening strategy that exploited a synthetic lethality between cytidine deaminases (CD) overexpression and homologous recombination inhibition. The screen was designed to select for compounds that induced synthetic lethality in CD-overexpressing cancer cells while sparing normal cells. According to our CYT split history records, Cyteir Therapeutics has had 2 splits. | |
|
Cyteir Therapeutics (CYT) has 2 splits in our CYT split history database. The first split for CYT took place on July 24, 1996. This was a 3 for 1
split, meaning for each share of CYT owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 3000 share position following the split. CYT's second split took place on September 18, 2014. This was a 2 for 1 split, meaning for each share of CYT owned pre-split, the shareholder now owned 2 shares. For example, a 3000 share position pre-split, became a 6000 share position following the split.
When a company such as Cyteir Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the CYT split history from start to finish, an original position size of 1000 shares would have turned into 6000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cyteir Therapeutics shares, starting with a $10,000 purchase of CYT, presented on a split-history-adjusted basis factoring in the complete CYT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/18/2021 |
|
| End date: |
03/15/2024 |
|
| Start price/share: |
$17.40 |
|
| End price/share: |
$3.02 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-82.64% |
|
| Average Annual Total Return: |
-47.19% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,736.04 |
|
| Years: |
2.74 |
|
|
|
| Date |
Ratio |
| 07/24/1996 | 3 for 1
| | 09/18/2014 | 2 for 1 |
|
|
Free CYT Email Alerts:
